Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy

Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds.

On May 30, Mineralys Therapeutics Inc. (NASDAQ:MLYS) provided compelling data for the clinical efficacy of lorundrostat during the 35th European Meeting on Hypertension and Cardiovascular Protection. This clinical update comes after the company’s strategic focus on assisting patients with chronic kidney disease (CKD) in dealing with the combined burden of uncontrolled blood pressure.

Pressmaster/Shutterstock.com

The Phase 3 Launch-HTN trial analysis formally demonstrated significant, placebo-adjusted systolic blood pressure reductions of 9.6 mmHg in CKD participants and 12.2 mmHg in non-CKD populations over a standard 12-week period. For individuals with baseline albuminuria, the targeted therapeutic agent demonstrated a strong 52.2% decrease in the urine albumin-to-creatinine ratio in addition to a very good safety profile with few verified cases of hyperkalemia.

By aggressively increasing the clinical value of its diverse offers across high-risk patient groups, the company is hoping to obtain official regulatory permissions. Additionally, the U.S. Food and Drug Administration is presently reviewing Lorundrostat. The final PDUFA target action date is scheduled for December 22, 2026.

Mineralys Therapeutics Inc. (NASDAQ:MLYS) engages in the development of therapeutics that target illnesses caused by dysregulated aldosterone. It is working on the development of lorundrostat, an aldosterone synthase inhibitor for cardiorenal conditions. These include chronic kidney disease, hypertension, and obstructive sleep apnea.

While we acknowledge the risk and potential of MLYS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MLYS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1